Research Grade Anti-Human TIGIT (BAT-6005) (HS739136)

Datasheet Share product Copy info

Price(USD): $

Spec:

100ug
1mg

Number:

Overview
Images
References
Datasheet

Overview

Catalog No.	HS739136
Description	Anti-Human TIGIT (BAT-6005) (HS739136) is a research-grade recombinant antibody targeting VSTM3. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Species reactivity	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Human
Isotype	IgG
Clone ID	BAT-6005
Expression system	Mammalian Cells
Clonality	Monoclonal
Target	VSTM3, TIGIT, V-set and transmembrane domain-containing protein 3, VSIG9, V-set and immunoglobulin domain-containing protein 9, T-cell immunoreceptor with Ig and ITIM domains
Endotoxin level	Please contact the lab for this information.
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	Q495A1
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternate Names	BAT-6005, BAT6005, BAT6005
Background	T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is a ~26 kDa protein. Inhibitory receptor that plays a role in the modulation of immune responses. Suppresses T-cell activation by promoting the generation of mature immunoregulatory dendritic cells. Upon binding to its ligands PVR/CD155 or NECTIN2/CD112, which are expressed on antigen-presenting cells, sends inhibitory signals to the T-cell or NK cell. Mechanistically, interaction with ligand leads to phosphorylation of the cytoplasmic tail by Src family tyrosine kinases such as FYN or LCK, allowing subsequent binding to adapter GRB2 and SHIP1/INPP5D. In turn, inhibits PI3K and MAPK signaling cascades. 1. Yu, X. et al. (2009) Nature immunology 10, 48-57. PMID: 19011627 2. Liu, S. et al. (2013) Cell death and differentiation 20, 456-64. PMID: 23154388 3. Li, M. et al. (2014) The Journal of biological chemistry 289, 17647-57. PMID: 24817116 4. Reches, A. et al. (2020) Journal for immunotherapy of cancer 8. PMID: 32503945
Note	For research use only. Not suitable for clinical or therapeutic use.